Highest-materiality recent filing
Dentsply Sirona Q1 adj EPS $0.27, down 39% YoY; net sales flat at $880M
GAAP net loss per share ($0.05); adjusted EPS $0.27 vs $0.44 in Q1 2025.
Q4 net sales $961M (+6.2% reported, +2.5% constant currency); reported diluted EPS ($0.74) from $144M impairments.
Dentsply Sirona appoints Forbes and McKeon to board; Deese retiring
James Forbes (former Morgan Stanley vice chairman) and Brian McKeon (former IDEXX CFO) join Board effective Feb 27, 2026.
Dentsply Sirona renews U.S. dental technology distribution agreement with Patterson Dental
Renewed non-exclusive agreement covers Dentsply Sirona's full portfolio including CEREC, Primescan, Axeos, and Orthophos systems.
Donald Zurbay appointed to Board effective Jan 10, 2026; former Patterson CEO/CFO and St. Jude Medical CFO.
Dentsply Sirona amends debt covenants; new leverage ratios step down to 3.50x, restricts dividends
New Total Leverage Ratio covenant: cannot exceed 4.25x (Q4 2025–Q2 2026) stepping down to 3.50x (Q3 2027+).
DENTSPLY SIRONA appoints Michael Pomeroy as interim CFO; CEO remains principal financial officer
Michael Pomeroy appointed interim CFO effective November 25, 2025.
CFO Matthew Garth separation agreement: $1.2M in payments, equity forfeiture, restrictive covenants
Matthew E. Garth's separation effective Nov 5, 2025; agreement signed Nov 7, 2025.
CFO Matthew Garth to depart Nov 5; CEO Scavilla takes interim CFO role
Matthew E. Garth will leave as EVP and CFO effective November 5, 2025.
Dentsply Sirona Q3 net sales down 5% to $904M; GAAP loss $2.14/share; cuts FY25 outlook
Net sales $904M, down 5.0% as-reported, 8.0% constant currency; GAAP net loss per share ($2.14).
SEC concludes investigation of Dentsply Sirona without enforcement action
SEC's Division of Enforcement closed its investigation initiated May 2022.
EVP, General Counsel & Secretary Richard Rosenzweig departs; becomes Special Legal Advisor
Richard C. Rosenzweig ceases role as EVP, Corporate Development, General Counsel and Secretary effective Oct 3, 2025 by mutual agreement.
Dentsply Sirona awards $2M retention stock options to SVP/Chief Supply Chain Officer
Retention grant of stock options with grant-date fair value of $2,000,000 to Tony Johnson, SVP and Chief Supply Chain Officer.
Dentsply Sirona Retains Wellspect Healthcare After Strategic Review, Ends Sale Process
Strategic review of Wellspect begun Feb 2025 completed Sep 8, 2025; company decided to retain the business.
Net sales $936M, down 4.9% (down 6.7% constant currency); GAAP net loss ($45M) or ($0.22) per share.
Dentsply Sirona appoints Daniel Scavilla as CEO; preliminary Q2 sales ~$935M and adj. EPS $0.50-0.52
Daniel Scavilla appointed President & CEO effective Aug 1, 2025, succeeding Simon Campion who departs July 31, 2025.
Dentsply Sirona issues $550M of 8.375% junior subordinated notes due 2055, repays $435M bridge loan
Issued $550M aggregate principal of 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due September 12, 2055.
Dentsply Sirona prices $550M 8.375% junior subordinated notes due 2055
$550M aggregate principal amount of 8.375% fixed-to-fixed reset rate junior subordinated notes due 2055.
Dentsply Sirona amends credit agreements to add leverage covenant, increase ratio limit to 65%
New financial covenant: senior debt to capitalization must not exceed 60%.
Dentsply Sirona appoints Matthew Garth as CFO, effective May 30, 2025
Matthew Garth named EVP & CFO; previously CFO & CAO of Scotts Miracle-Gro.
All 11 director nominees elected with >94% of votes cast; broker non-votes of ~11.3 million.
On May 27, 2025, the Board of Directors (the “Board”) of DENTSPLY SIRONA Inc. (the “Company”) appointed Matthew E. Garth as the Company’s Executive Vice President & Chief Financial Officer, effective as of May 30, 2025 (the “Effective Date”).
Max materiality 0.85 · Median 0.65 · Most common event leadership